Robert W. Gao

Robert W. Gao

Auto-generated profile, based on publicly available information

Robert W. Gao

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in European Urology Oncology
Verified
Journal Article
Closed access
MDMatthew P. Deek
Matthew P. Deek
KTKekoa Taparra
Kekoa Taparra
RPRyan Phillips
Ryan Phillips
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
RGRobert W. Gao
Robert W. Gao
BSBradley J. Stish
Bradley J. Stish


25 May 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
RGRobert W. Gao
Robert W. Gao
TMTrey C. Mullikin
Trey C. Mullikin
KAKhaled A. Aziz
Khaled A. Aziz
AAArslan Afzal
Arslan Afzal
NSNa L. Smith
Na L. Smith
RMRobert W. Mutter
Robert W. Mutter
To report oncologic, physician-assessed, and patient-reported outcomes (PROs) for a group of women homogeneously treated with modern, skin-sparing multifield optimized pencil-beam scanning proton (intensity modulated proton therapy [IMPT]) postmastectomy radiation therapy (PMRT). We reviewed consecutive patients who received unilateral, curative-intent, conventionally fractionated IMPT PMRT between 2015 and 2019. Strict constraints were applied to limit the dose to the skin and other organs at risk. Five-year oncologic outcomes were analyzed. Patient-reported outcomes were evaluated as part of a prospective registry at baseline, completion of PMRT, and 3 and 12 months after PMRT. A total of 127 patients were included. One hundred nine (86%) received chemotherapy, among whom 82 (65%) received neoadjuvant chemotherapy. The median follow-up was 4.1 years. Five-year locoregional control was 98.4% (95% CI, 93.6-99.6), and overall survival was 87.9% (95% CI, 78.7-96.5). Acute grade 2 and 3 dermatitis was seen in 45% and 4% of patients, respectively. Three patients (2%) experienced acute grade 3 infection, all of whom had breast reconstruction. Three late grade 3 adverse events occurred: morphea (n = 1), infection (n = 1), and seroma (n = 1). There were no cardiac or pulmonary adverse events. Among the 73 patients at risk for PMRT-associated reconstruction complications, 7 (10%) experienced reconstruction failure. Ninety-five patients (75%) enrolled in the prospective PRO registry. The only metrics to increase by >1 point were skin color (mean change: 5) and itchiness (2) at treatment completion and tightness/pulling/stretching (2) and skin color (2) at 12 months. There was no significant change in the following PROs: bleeding/leaking fluid, blistering, telangiectasia, lifting, arm extension, or bending/straightening the arm. With strict dose constraints to skin and organs at risk, postmastectomy IMPT was associated with excellent oncologic outcomes and PROs. Rates of skin, chest wall, and reconstruction complications compared favorably to previous proton and photon series. Postmastectomy IMPT warrants further investigation in a multi-institutional setting with careful attention to planning techniques.

12 October 2022 in Head & Neck
Verified
Journal Article
Closed access
RGRobert W. Gao
Robert W. Gao
DRDavid M. Routman
David M. Routman
WHWilliam S. Harmsen
William S. Harmsen
SESasha Ebrahimi
Sasha Ebrahimi
RFRobert L. Foote
Robert L. Foote
SLScott C. Lester
Scott C. Lester

1 November 2018 in Practical Radiation Oncology
Verified
Journal Article
Closed access
RGRobert W. Gao
Robert W. Gao
SPSean S. Park
Sean S. Park
JJJames W Jakub
James W Jakub
THTina J. Hieken
Tina J. Hieken
ACAmy L. Conners
Amy L. Conners
BSBradley J. Stish
Bradley J. Stish

1 March 2022 in Practical Radiation Oncology
Verified
Journal Article
Closed access
RGRobert W. Gao
Robert W. Gao
RFRobert L. Foote
Robert L. Foote
YGYolanda I. Garces
Yolanda I. Garces
DMDaniel J. Ma
Daniel J. Ma
MNMichelle Neben-Wittich
Michelle Neben-Wittich
SLScott C. Lester
Scott C. Lester